AI powered Biotech startup Peptilogics secured $35.4 Million


Peptilogics, a Pittsburgh-based clinical-stage biotechnology company has now secured $35.4 million in a Series B funding round.

Peptilogics is founded by Jonathan Steckbeck in the year 2013. It combines proven drug development expertise with the proprietary Artificial Intelligence and Machine Learning methods to find new connections among the diverse biomedical data across the entire drug development spectrum to map a new universe of the peptide sequences.

Executive Opinion

Jonathan Steckbeck, Ph.D., MBA, Founder, and CEO of Peptilogics, said, "We are thrilled to have the support of this visionary investor syndicate to accelerate our growth. Our goal is to enable the industry by unlocking the full potential of peptides through the development of technologies that facilitate the rapid design of more effective therapeutics."

Presight Capital co-founder Christian Angermayer, said, "We are building the world’s leading discovery and development platform for peptides, as we believe some of the world’s most impactful medicines in the future will be peptides."

Peptilogics's Latest Funding

The round was backed by the Presight Capital, with participation from Founders Fund and Peter Thiel.

The company as of now has plans to use the new funds to expand its computational platform and invest in technologies to improve its drug design engine.
PC: Pablo, Pixabay

Note: We at TechSutram take our ethics very seriously. More information about it can be found here.
Udit Agarwal Opinions expressed by techsutram contributors are their own. More details

Udit Agarwal is a Digital Marketer and a Content Marketing Specialist, He enjoys technical as well as non-technical writing. His passion and urge for gaining new insights on gadgets, smartphones and technology has led him to Techsutram. He quenches his thirst for technology through his action oriented writing skills and a profound ability to stay up to date with latest industry trends.

No comments:

Post a Comment

    Your valuable comments are welcome. (Moderated)